Product category:
Clinical chemistry analysis
News Release from: Perkin Elmer LAS (UK) | Subject: XMap
Edited by the Laboratorytalk Editorial
Team on 12 January 2006
Deal boosts high volume disease
screening
PerkinElmer and Luminex have announced a long-term licencing agreement to provide PerkinElmer access to Luminex's xMap technology and assay development capabilities of the Luminex Bioscience group
PerkinElmer will utilise Luminex's xMap technology in several areas of life science research and in vitro diagnostics Focus areas are expected to include biomarker panels for pharmaceutical development and Adme/Tox as well as developing in vitro diagnostics in maternal, neonatal and prenatal health
This article was originally published on Laboratorytalk on 19 Apr 2002 at 8.00am (UK)
Related stories
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
Manage the entire gene expression process
With microarray labs generating more than one million primary data points daily, this gene expression data management software could speed up actual gene and drug discovery
PerkinElmer also plans to standardise its multiplex assay development on the Luminex xMap platform.
Demand for multiplex testing, or performing multiple biomedical tests on a single sample, continues to accelerate for disease screening and discovery markets.
To meet this need, PerkinElmer plans to offer the Luminex xMap platform as part of its strategy to provide its customers leading products in the area of high volume disease screening.
Further reading
Protein workstation details revealed
Claimed to be the first of its kind, this workstation fully automates the processing of microscope slide-based protein microarrays
More genes in human cDNA microarray
Human cDNA microarray system for researchers seeking access to premium gene content as well proprietary detection technology for ultra-sensitive gene expression results
"Providing our customers with access to a proven multiplexing system is essential to assist their specific research and development needs and long-term growth," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"We have selected Luminex's xMap technology as a recognised industry benchmark in multiplexed life science research and diagnostics applications.
"We look forward to working closely and collaboratively to benefit our respective customers".
Patrick Balthrop, Luminex's president and chief executive officer, commented: "This agreement with PerkinElmer is a prime example of our company's growing emphasis on establishing long-term partnerships with market leaders in segments of strategic significance to Luminex.
"In this relationship with PerkinElmer we are not only providing new markets and customers with access to the Luminex xMap technology, we are also partnering with a premier company with significant market presence.
"We are excited to have PerkinElmer on board and look forward to pursuing additional collaborative opportunities with them in the future".
Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.
The company's xMap system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.
xMap technology is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.
xMap received the 2005 clinical diagnostics technology of the year award from Frost and Sullivan.
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
